Immunoprecise Antibodies Ltd IPA

Technology Scientific & Technical Instruments

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.

NDAQ:IPA - Post by User

Immunoprecise Antibodies Ltd

<< Previous

Bullboard Posts

Next >>

Post by TheBearInTheWoodson Aug 13, 2021 11:13am

251 Views

Post# 33700608

Phase II Clinical Data going for third party review

Phase II Clinical Data going for third party review

"Arch Biopartners Inc. has provided an update that the analysis of the results of the phase II trial of its lead drug LSALT peptide (metablok) is continuing and will be disclosed to the public following third party, scientific peer review."

ARCH.V - 56% held by insiders

Canadian Innovation Funded Phase II human trial on Organ inflammation

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading